Literature DB >> 7737776

Open randomized comparison of itraconazole versus terbinafine in onychomycosis.

R Arenas1, J Domínguez-Cherit, L M Fernández.   

Abstract

BACKGROUND: Onychomycoses are among the most frequent nail diseases. The principal agents are dermatophytes. Itraconazole and terbinafine are two effective and systemic antimycotics. Previous trials have shown, that treatment schedules with effective concentrations for 3 months cause drug deposits in nail plates that persist 6 months after the end of the treatment.
METHODS: A comparative, open, prospective study was carried out with random assignment of patients. The first group included 27 patients under treatment with 200 mg of itraconazole once daily for 3 months. The second group included 26 patients treated with 250 mg of terbinafine for 3 months. Both series of patients were followed for 6 additional months.
RESULTS: Both groups were similar in age, sex, and history of onychomycosis. Trichophyton rubrum was the main isolated agent in all patients. The percentage of diseased nails was similar in both groups affecting predominantly the first toenail. Treatment was highly effective and differences between groups were not significant. The rate of adverse events was 21% in the itraconazole group and 47% in the terbinafine group.
CONCLUSIONS: Itraconazole and terbinafine are two drugs of choice in dermatophytic onychomycosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7737776     DOI: 10.1111/j.1365-4362.1995.tb03600.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  12 in total

Review 1.  Oral antifungal medication for toenail onychomycosis.

Authors:  Sanne Kreijkamp-Kaspers; Kate Hawke; Linda Guo; George Kerin; Sally Em Bell-Syer; Parker Magin; Sophie V Bell-Syer; Mieke L van Driel
Journal:  Cochrane Database Syst Rev       Date:  2017-07-14

Review 2.  A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis.

Authors:  A K Gupta; N H Shear
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

Review 3.  Which antifungal agent for onychomycosis? A pharmacoeconomic analysis.

Authors:  V N Joish; E P Armstrong
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 4.  Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections.

Authors:  M Haria; H M Bryson; K L Goa
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 5.  Management of onychomycoses.

Authors:  M Niewerth; H C Korting
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

6.  Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis.

Authors:  A K Gupta
Journal:  Pharmacoeconomics       Date:  1998-02       Impact factor: 4.981

7.  Onychomycosis. New therapies for an old disease.

Authors:  A K Gupta; R K Scher; P De Doncker; D N Sauder; N H Shear
Journal:  West J Med       Date:  1996-12

8.  Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group.

Authors:  M Bräutigam; S Nolting; R E Schopf; G Weidinger
Journal:  BMJ       Date:  1995-10-07

9.  The effects of laser irradiation on Trichophyton rubrum growth.

Authors:  Emre Vural; Harry L Winfield; Alexander W Shingleton; Thomas D Horn; Gal Shafirstein
Journal:  Lasers Med Sci       Date:  2007-09-28       Impact factor: 3.161

Review 10.  Onychomycosis: pathogenesis, diagnosis, and management.

Authors:  B E Elewski
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.